KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization Amortization Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Working Capital Change in Working Capital Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Gsk (GSK) Other Working Capital Changes (2021 - 2022)

Gsk has reported Other Working Capital Changes over the past 3 years, most recently at -$900.4 million for Q1 2022.

For Q1 2022, Other Working Capital Changes fell 21.14% year-over-year to -$900.4 million; the TTM value through Mar 2022 reached -$1.5 billion, down 185.9%, while the annual FY2020 figure was $158.5 million, 76.79% down from the prior year.
Other Working Capital Changes for Q1 2022 was -$900.4 million at Gsk, down from -$743.2 million in the prior quarter.
Over five years, Other Working Capital Changes peaked at -$743.2 million in Q1 2021 and troughed at -$900.4 million in Q1 2022.